Obermatt
See Similar Stocks →

Boryung

KSC:003850 · KR7003850005
PharmaceuticalsSmall

360

94
EV / EBIT64
Price / Owner Earnings48
Owner Earnings Yield91
Dividend Yield83
Price/Sales80
EV / Gross Profit77
Price/Book80
Return on Capital67
Cash Return on Capital88
Return on Equity79
EBIT Margin56
Gross Profitability58
Cash Conversion65
Accruals63
Owner Earnings Margin84
Sales growth12
Profit Growth37
Long-Term EPS Growth47
Owner Earnings Growth73
Reinvestment93
Price momentum65
Debt load50
Refinancing57
Debt Payback38
Liquidity52
Analyst ratings34
Opinion Changes50
Price Target Upside35
Market mood84
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Boryung clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Founded1963
Employees47
Websiteboryung.co.kr/en
ISINKR7003850005
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
CardiovascularDiabetesInternal DiseasesBiotechnologyHealth CareMedicalPharmaceutical

Description

Analysis

Quality compounder

Boryung Corporation is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is attractive. You pay 5.4× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
80
2023202420252026

All-time high

86

Jan 2025

All-time low

31

Jan 2023

Average rank

68

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
80
80
85
65
Price/Earnings
50
63
44
40
Price/Book
80
48
42
35
Dividend Yield
83
32
35
36
Value (overall)
94
52
48
37

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Boryung with its peers
Bora Pharmaceuticals
TAI:6472
27
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Chongkundang Holdings
KSC:001630
56
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Il Dong Pharmaceutical
KSC:249420
53
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Jeil Pharmaceutical
KSC:271980
70
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Samsung Pharm
KSC:001360
—
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →